Decursin and Doxorubicin Are in Synergy for the Induction of Apoptosis via STAT3 and/or mTOR Pathways in Human Multiple Myeloma Cells
Figure 4
Effect of decursin on mitochondria-dependent apoptosis in doxorubicin-treated multiple myeloma cells. (a) U266 cells were treated with decursin (40 or 80 M) and/or doxorubicin (0.5 or 1 M) for 24 h and subjected to western blotting for PARP and caspase-3. (b) MM.1S and RPMI8226 cells were treated with decursin (40, 80 M, resp.) and/or doxorubicin (0.25, 1 M, resp.) for 24 h. Western blotting was performed for PARP. (c) U266 cells were treated with decursin (80 M) and/or doxorubicin (1 M) for 8 or 16 h, and with decursin (40 or 80 M) and/or doxorubicin (0.5 or 1 M) for 24 h. Western blotting was performed for caspase-9. (d) U266 or MM.1S cells were treated with decursin (80 M) and/or doxorubicin (0.5 or 1 M) for 24 h and stained with tetramethylrhodamine ethyl ester (TMRE) for 30 min at 37°C, and mitochondrial membrane potential (MMP) was detected by flow cytometry. Graphs represent the percentages of MMP. Data are presented as means ± SD for triplicate experiments. *, and **, versus untreated control. #, , versus doxorubicin-treated cells.
